RNAi drugs startup Arcturus Therapeutics this week announced that it has raised $5 million in a Series A round of financing, which comes just months after the company pulled in $1.5 million in seed money.

With the additional funding, Arcturus is now on track to unveil its lead product candidate early next year, with phase I testing beginning as early as 2015, company officials told Gene Silencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.